Skip to main content
04_News Effland
© Alessandro Winkler / UKB

News categories: Honors & Funding

Women TechEU Start-Up Funding for University of Bonn Spin-Off

SmartContrast reduces use of contrast agents

relios.vision GmbH, a University of Bonn start-up that has developed the SmartContrast software, receives funding from the European Innovation Council’s (EIC) Women TechEU program. ImmunoSensation² member Prof. Alexander Effland, together with experts from the fields of medicine and mathematics is involved in the company. Using artificial intelligence, SmartContrast aims to lower the use of contrast agents for magnetic resonance imaging of the brain, thus reducing examination costs and potential risks for patients and the environment.

The program aims to support deep tech start-ups led in part by women, as currently only about 15 percent of all start-ups are counting women among their founding members. Even today in the EU only about five percent of risk capital goes to mixed-gender founding teams, while the figure for women-only founding teams (a mere two percent) is even lower. Start-up companies dedicated to innovative technologies are facing an even bigger gender gap.

“We’re very pleased about the funding that enables us to proceed with the next steps in the medicinal product development of our SmartContrast software,” states Dr. Katerina Deike-Hofmann, relios.vision GmbH co-founder and managing partner and also physician at the University Hospital Bonn’s Neuroradiology Clinic.

ImmunoSensation2 member Prof. Alexander Effland from the Institute for Applied Mathematics at the University of Bonn, also forming part of the SmartContrast team, comments: “The interdisciplinary cooperation has been a very beneficial experience for everyone involved. I’m glad that our mathematical research helps hospitals on the path to becoming more sustainable and reducing the impact on the environment.”

Prof. Alexander Radbruch, Director of the Neuroradiology Clinic at the University Hospital Bonn, stresses the great innovation potential science start-ups carry: “relios.vision GmbH serves as a very good example for research leading to the creation of real products and benefitting our patients.”

Selected start-ups receive grants of €75,000 as well as mentoring, coaching and access to an EU-wide network of entrepreneurs. All companies are characterized by their strong power to innovate, excellent results both in research and in development, their impact in the EU and a strong female representation on managing boards or founding teams. Among the successful applicants were a total of 134 companies stemming from 26 EU countries and 16 industry sectors, 18 of which came from Germany.

Supporting women at the University of Bonn not only plays a key role with regards to research but also when it comes to starting a company. The enaCom Transfer Center bundles specific support for female entrepreneurs. Further information is available on the enaCom web page.

Related news

Zwei Personen: Links Prof. Pröpstl und rechts Prof. Boztug

News categories: Honors & Funding

University of Bonn and University Hospital Bonn strengthen early-career clinical scientists

The Faculty of Medicine at the University of Bonn and the University Hospital Bonn (UKB) are jointly launching the EKFS doctoral program IMMUNE PILOT, which introduces medical students to clinical-scientific research at an early stage. The structured program is positioned at the interface of immunology, neuroscience, and genetics and is aimed at students with a strong interest in research who aspire to pursue a career as clinician scientists. The program is funded by the Else Kröner-Fresenius Foundation (EKFS).
View entry
PrepAIred

News categories: Honors & Funding

Precise active ingredients against pancreatic cancer

Pancreatic cancer remains one of the deadliest forms of cancer. At the German Cancer Congress 2026, German Cancer Aid is now presenting three large-scale projects that it is funding as part of its “German Alliance for Pancreatic Cancer” funding priority. In the funded project PrepAIred, Bonn researchers , in cooperation with the University of North Carolina (USA), want to use AI-based protein design to specifically combat pancreatic cancer. German Cancer Aid is funding the project with a total of 1.99 million euros over a period of four years.
View entry
Gruppenbild Preistrager Lisec Artz Preisverleihung

News categories: Honors & Funding

Niklas Klümper and Varun Venkataramani receive Lisec-Artz Prize

Dr. Varun Venkataramani of the Faculty of Medicine at Heidelberg University and ImmunoSensation² member Dr. Niklas Klümper of the University Hospital Bonn have been awarded the Lisec Artz Prize for their outstanding cancer research. The University of Bonn Foundation and the University of Bonn Faculty of Medicine presented the awards to the two researchers on Tuesday, November 18, 2025 at the University Hospital Bonn (UKB) as part of the Cluster Science Days event held by the ImmunoSensation² Cluster of Excellence. The prize is worth a total of 15,000 euros.
View entry

Back to the news overview